Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06018558 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy
A Phase 1 study of Geographic Atrophy, sponsored by Ocugen.
- Active
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 12
- Study locations
NCT06018558 is a Phase 1 study of Geographic Atrophy that is active but no longer recruiting, run by Ocugen. The registered enrollment target is 60 participants, below the 220-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (73% lower). The trial reports 12 study locations across 10 states.
The verdict
NCT06018558, a Phase 1 study of Geographic Atrophy, is active but no longer recruiting, sponsored by Ocugen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (AMD). This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 60 subjects.
Conditions Studied
Interventions
- GENETIC OCU410
Study Locations (12)
Texas
- B) Retina Consultants of Texas - Bellaire
- A) Retina Foundation of the Southwest - Dallas
- Valley retina Institute - McAllen
Arizona
- Associated Retina Consultants - Phoenix
Florida
- Advanced Research, LLC - Coral Springs
Indiana
- Miidwest Eye Institute - Carmel
Mississippi
- Mississippi Retina Associates - Jackson
Missouri
- The Retina Institute - St Louis
New Jersey
- Mid Atlantic Retina - Cherry Hill
North Carolina
- Duke Eye Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-02-23 |
| Est. Completion | 2026-05-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06018558
The ClinicalTrials.gov registry entry for NCT06018558 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 220-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (73% lower). The listed sponsor is Ocugen, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Geographic Atrophy appearing as the primary indexed condition, and to 1 intervention - of which OCU410 is the first listed.
NCT06018558 reports 12 study locations spanning 10 distinct geographic areas - top geographies include Texas, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT06018558 about?
NCT06018558 is a clinical study titled "Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy". This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (AMD). This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 60 subjects.
What is the current status of trial NCT06018558?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2023-02-23. Estimated completion is 2026-05-29.
What conditions does trial NCT06018558 study?
This clinical trial studies the following conditions: Geographic Atrophy.
What interventions are being tested in trial NCT06018558?
The interventions under investigation include: OCU410 (GENETIC).
Who is sponsoring clinical trial NCT06018558?
This trial is sponsored by Ocugen, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06018558 being conducted?
This trial has 12 study locations across Arizona, Florida, Indiana, Mississippi, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
RECRUITING · Phase 1
-
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
RECRUITING · Phase 1
-
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
RECRUITING · Phase 1
-
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 1
-
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.